Novotech Executive Team at J.P. Morgan Healthcare Conference: Global CRO Designed for Biotechs Across 25 Regions

San Francisco, CA, USA - Novotech, a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase announced today that  it will have the largest ever presence at the J.P.Morgan Healthcare Conference in San Francisco, CA, USA, January 8-11, 2024.  

This marks a significant milestone for the company as it has finalized the integration of its acquisitions of EastHORN and CBR International solidifying its position as a leading global CRO for the biotech sector.

The executive team will be participating in the following partnering platforms during the Conference:

• CTIC – January 7, 2024, at the Intercontinental San Francisco
• Biotech Showcase – January 8 -10, 2024, at the San Francisco Hilton
• BIO Partnering – January 8 -11, 2024, at the San Francisco Marriott Marquis
• RESI – January 9, 2024, at the Marines Memorial Club 

Schedule a meeting with the team 

Novotech offers an integrated and scaleable clinical development approach across more than 25 geographies and is highly regarded for its scientific expertise in key therapeutic areas including:

• Oncology
• Cell & Gene Therapy
• Liver disease
• Infectious diseases and vaccines
• Orphan and rare diseases

Novotech has more than 3,000 employees across 34 office locations in the US, Greater China, South Korea, Australia, New Zealand, and Europe.

The CRO offers biotechs a unique and unparalleled suite of early to late-phase services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. Its commitment to collaboration is evident in the 50 Leading Site Partnership agreements it has signed over the past three years.